ADC Therapeutics SA (ADCT) 株式分析

企業概要

ADC Therapeutics SA is a biotechnology enterprise headquartered in Switzerland and the United States that specializes in developing antibody drug conjugate (ADC) technology platforms designed to treat oncological conditions. This company operates within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on high-risk, high-reward research and development phases rather than established cash-flow generation from mature products. The firm currently maintains a market capitalization of $477.69M and employs a workforce of 188 individuals to support its operational activities. With an annual revenue of $81.36M, the company's financial scale indicates a mid-sized biopharmaceutical entity that is generating significant sales but has not yet achieved profitability, reflecting the typical financial trajectory of firms still navigating the commercialization of their flagship product, ZYNLONTA, which received accelerated approval from the U.S. Food and Drug Administration.

財務健全性

ADC Therapeutics SA reported a trailing twelve-month revenue of $81.36M, yet this generated a net income of $-142,623,008 and an EBITDA of $-105,390,000, revealing a substantial disparity between top-line sales and bottom-line results. This significant gap between revenue and net income highlights an aggressive cost structure where operating expenses, likely driven by R&D and commercialization costs for ZYNLONTA, are exceeding gross revenues, resulting in a gross margin of -32.2%. Furthermore, the operating margin stands at -69.3%, while the profit margin is severely depressed at -175.3%, indicating that for every dollar of revenue generated, the company incurs losses that far exceed that dollar amount before accounting for non-operating factors. The company's free cash flow is negative at $-103,812,000, which signifies a lack of internal financial flexibility and a reliance on external capital markets to fund ongoing operations and growth initiatives. On the liability side, the firm holds $261.34M in cash and cash equivalents against $439.55M in total debt, creating a negative net cash position that suggests a leveraged balance sheet typical of pre-profitability biotech firms. Despite the debt load, the current ratio is a healthy 4.37, indicating that the company possesses sufficient current assets to cover its short-term obligations without immediate distress. Additionally, the return on equity is listed as N/A due to the negative equity base, while the return on assets is -20.6%, demonstrating that management's efforts have resulted in a negative return on the capital invested in the business assets.

バリュエーション評価

The valuation metrics for ADC Therapeutics SA reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -2.52, implying that earnings-based valuation models are currently inapplicable and that the market is pricing the stock based on non-GAAP or alternative metrics. The price-to-book ratio is recorded as -2.54, a figure that indicates the market is valuing the company at a discount relative to its book value, a common phenomenon for firms with significant intangible assets or accumulated losses that depress the book equity. Alternative valuation measures such as the price-to-sales ratio of 5.87 and an EV/EBITDA of -6.22 suggest that investors are willing to pay a premium for future revenue potential despite current financial losses, placing emphasis on the growth trajectory of the antibody drug conjugate platform. Regarding trading range, the stock has reached a 52-week high of $4.98 and a 52-week low of $1.05; however, without a specific current share price provided in the source data, the precise percentage deviation from these bounds cannot be calculated, though the wide range suggests high volatility. The stock exhibits a beta of 1.95, which indicates that the share price is nearly twice as volatile as the broader market, meaning that price movements will likely be amplified by market swings, presenting higher risk for risk-averse participants.

Growth & Income

ADC Therapeutics SA demonstrated a robust revenue growth rate of 36.4% year-over-year, whereas the earnings growth rate is N/A due to the company's continued losses, implying that top-line expansion is currently outpacing profitability improvements. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash reserves are being reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology companies in the growth phase, where capital allocation prioritizes the advancement of the ADC technology platform over immediate income generation. Consequently, the overall growth and income profile of ADC Therapeutics SA is characterized by rapid revenue expansion and a total absence of dividend income, positioning the stock as a pure-play growth vehicle dependent on future milestone achievements and regulatory approvals to transition to profitability.